Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT03271697

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03271697
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03271697. Randomized; triple masking; primary purpose treatment. Start 2017-09 (anticipated); primary completion 2020-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
Acronym
AMASH
Condition
Aneurysmal Subarachnoid Hemorrhage
Intervention (Drug)
Astragalus Membranaceus
Intervention (Drug)
Placebo
Lead sponsor
China Medical University Hospital (class: other)

Record details

Record id
cardio:ct-nct03271697
Content hash
c50501863618e557495c3168f137c9a827e5f13643ff8e5f1de355a622685ccf